Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Breast Cancer Clinical Trial

Official title:

Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Patients With Resected HER2 + Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00436566
• Other study ID #: CDR0000533793
• Secondary ID: P30CA015083RC063
• Status: Completed
• Phase: Phase 2
• Start date: March 16, 2007
• Est. completion date: July 22, 2019

Study information

• Verified date: January 2019
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with trastuzumab and lapatinib after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This randomized phase II trial is studying the side effects and how well giving doxorubicin together with cyclophosphamide followed by trastuzumab, paclitaxel, and lapatinib works in treating patients with early-stage HER2-positive breast cancer that has been removed by surgery.

Description:

OBJECTIVES:

Primary

• Determine the cardiac safety of adjuvant therapy comprising doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel, trastuzumab (Herceptin®), and lapatinib ditosylate in patients with resected early-stage HER2-positive breast cancer.

Secondary

• Determine the adverse event profile of this regimen in these patients.

• Determine the cumulative incidence of cardiac events in patients treated with this regimen.

• Determine the LVEF in patients treated with this regimen.

• Determine the disease-free and overall survival of patients treated with this regimen.

• Compare selected quality-of-life (QOL) questionnaires in these patients.

• Evaluate QOL of patients treated with this regimen.

• Determine the cumulative incidence of pulmonary events in patients treated with this regimen.

Tertiary

• Compare Veridex CellSearch system vs quantitative reverse transcriptase polymerase chain reaction for detecting circulating tumor cells.

• Determine the relationship between serum levels of HER1 and HER2 and response to treatment.

• Evaluate cardiac markers (i.e., troponin-T, troponin-I, brain natriuretic peptide, and creatine kinase MB isoenzyme) at baseline.

• Determine the association between abnormal levels of cardiac markers and incidence of cardiac adverse events.

• Evaluate patterns of 500 metabolites in plasma in patients treated with this regimen and determine the association between metabolite patterns/molecular signatures and cardiotoxicity.

• Determine the time course of these molecular signatures and evaluate whether they are accurate predictors of cardiotoxicity that precede other evidence of cardiotoxicity (e.g., changes in left ventricular function seen by echocardiogram or MUGA scan).

• Compare metabolic signatures of cardiotoxicity with known laboratory evidence of cardiac damage (e.g., troponins or brain natriuretic peptide) in terms of sensitivity and specificity.

OUTLINE: This is a randomized, pilot, multicenter study. Patients are stratified according to educational level (less than high school vs high school or GED vs formal education beyond high school).

Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 2-3 weeks for 4 courses. Patients then receive paclitaxel IV over 60 minutes and trastuzumab (Herceptin®) IV over 90 minutes on days 1, 8, and 15 and oral lapatinib ditosylate on days 1-21. Treatment with paclitaxel, trastuzumab, and lapatinib repeats every 3 weeks for up to 4 courses. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21. Treatment with trastuzumab and lapatinib ditosylate repeats every 3 weeks for up to 12 courses.

Patients complete Linear Anologue Self Assessment (LASA) and Symptoms Distress Scale (SDS) questionnaires, including fatigue, diarrhea, and rash assessment, at baseline, after 2-3, 5-6, and 18 months of treatment, and 5 years after completion of treatment. Patients are also randomized to 1 of 2 arms to complete additional quality of life questionnaires at these same time points.

• Arm I: Patients complete EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires.

• Arm II: Patients complete FACT-B questionnaire. Blood samples are acquired periodically throughout and at the completion of study treatment. Samples are analyzed for circulating tumor cells by Veridex CellSearch system, quantitative reverse transcriptase polymerase chain reaction, and liquid chromatography with tandem mass spectrometry, soluble HER1- and HER2-receptor concentrations, circulating cardiac markers, and metabolic markers for possible correlation with cardiac events.

After completion of study treatment, patients are followed periodically for up to 10 years.

PROJECTED ACCRUAL: A total of 109 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 122
• Est. completion date: July 22, 2019
• Est. primary completion date: April 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of early-stage breast cancer

• HER2 positive by immunohistochemistry (IHC) (3+) or fluorescent in situ hybridization (FISH)

• Ductal carcinoma in situ (DCIS) components should not be counted in the determination of degree of IHC staining or FISH amplification

• No locally advanced tumors (i.e., T4) at diagnosis, including the following:

• Tumors fixed to chest wall

• Peau d'orange

• Skin ulcerations or nodules

• Clinical inflammatory changes (e.g., diffuse brawny cutaneous induration with an erysipeloid edge)

• Has undergone mastectomy or lumpectomy with axillary node or sentinel node dissection within the past 84 days

• Patients who have undergone a mastectomy must meet the following criteria:

• No evidence of gross or microscopic tumor (i.e., invasive DCIS) at the surgical resection margins noted in final surgery or pathology reports

• Patients with close margins are eligible

• Radiation therapy is required for 4 or more positive lymph nodes and must be started after completion of chemotherapy

• Patients who have undergone a lumpectomy with axillary node or sentinel node dissection must meet the following criteria:

• No evidence of invasive cancer or DCIS at the surgical resection margins

• No gross residual adenopathy

• Planning to undergo radiation therapy to the breast with or without regional lymphatics after completion of chemotherapy

• No active hepatic or biliary disease

• Patients with liver metastases, stable chronic liver disease, Gilbert's syndrome, or asymptomatic gallstones are eligible

• Hormone receptor status:

• Estrogen receptor and progesterone receptor status known

PATIENT CHARACTERISTICS:

• Male or female

• Menopausal status not specified

• ECOG performance status 0-2

• Absolute neutrophil count = 1,500/mm³

• Platelet count = 100,000/mm³

• Hemoglobin = 10.0 g/dL

• Bilirubin = 1.5 times upper limit of normal (ULN)

• AST and ALT = 2.5 times ULN

• Alkaline phosphatase = 2.5 times ULN

• Creatinine normal OR creatinine clearance = 60 mL/min

• LVEF = 50% by MUGA scan or echocardiogram

• Able to complete questionnaire(s) by themselves or with assistance

• Able and willing to provide blood and tissue samples

• No known sensitivity to benzyl alcohol

• No sensory neuropathy = grade 2

• No active cardiac disease, including any of the following:

• Myocardial infarction within the past 6 months

• Prior or concurrent congestive heart failure

• Prior or concurrent arrhythmia or cardiac valvular disease requiring medications or that is clinically significant

• Uncontrolled hypertension, defined as diastolic blood pressure (BP) >100 mm Hg or systolic BP > 200 mm Hg on 2 separate occasions = 14 days apart

• Clinically significant pericardial effusion

• Prior or concurrent uncontrolled or symptomatic angina

• Other cardiac condition that, in the opinion of the treating physician, would put the patient at hazardous risk

• No history of allergic reactions attributed to compounds of similar chemical or biologic composition as lapatinib ditosylate

• No uncontrolled intercurrent illness including, but not limited to, the following:

• Ongoing or active infection

• Psychiatric illness or social situations that would preclude study compliance

• Able to swallow and retain oral medication

• No history of gastrointestinal (GI) disease resulting in an inability to take oral medication, including any of the following:

• Malabsorption syndrome

• Requirement for IV alimentation

• Prior surgical procedures affecting absorption

• Uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 6 months after completion of study treatment

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer

• No primary breast radiation therapy as part of breast-conserving treatment

• No prior anthracycline or taxane therapy for any malignancy

• No prior epidermal growth factor receptor-targeting therapies (e.g., gefitinib, cetuximab, erlotinib hydrochloride, rituximab, trastuzumab [Herceptin®], lapatinib ditosylate, panitumumab, or nimotuzumab)

• At least 14 days since prior and no concurrent CYP3A4 inducers, including the following:

• Rifamycin-class antibiotics (e.g., rifampin, rifabutin, or rifapentine)

• Anticonvulsants (e.g., phenytoin, carbamazepine, or barbiturates [e.g., phenobarbital])

• Antiretrovirals (e.g., efavirenz or nevirapine)

• Glucocorticoids (e.g., oral cortisone, hydrocortisone, prednisone, methylprednisolone, or dexamethasone)

• Daily oral dexamethasone = 1.5 mg (or equivalent) allowed

• Modafinil

• Hypericum perforatum (St. John's wort)

• At least 7 days since prior and no concurrent CYP3A4 inhibitors, including the following:

• Antibiotics (e.g., clarithromycin, erythromycin, or troleandomycin)

• Antifungals (e.g., itraconazole, ketoconazole, fluconazole [> 150 mg daily], or voriconazole)

• Antiretrovirals and protease inhibitors (e.g., delaviridine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, or lopinavir)

• Calcium channel blockers (e.g., verapamil or diltiazem)

• Antidepressants (e.g., nefazodone or fluvoxamine)

• Gastrointestinal agents (e.g., cimetidine or aprepitant)

• Grapefruit and grapefruit juice

• At least 6 months since prior and no concurrent amiodarone

• No herbal or alternative medicines or supplements = 14 days before, during, and for 30 days after completion of study treatment

• No concurrent hormonal agents (e.g., birth control pills, ovarian hormonal replacement therapy, or raloxifene)

• Adjuvant hormonal agents (e.g., tamoxifen, aromatase inhibitors) allowed after completion of chemotherapy as part of treatment for breast cancer

• No concurrent antiretroviral therapy for HIV-positive patients

• No concurrent digitalis or beta-blockers for congestive heart failure

• No concurrent arrhythmia or angina pectoris medication

• No other concurrent investigational agents or anticancer therapies, including cytotoxic agents or immunotherapy

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Cardiac Toxicity
• Cardiotoxicity

Intervention

Biological:
• trastuzumab

Drug:
• cyclophosphamide

• doxorubicin hydrochloride

• lapatinib ditosylate

• paclitaxel

Genetic:
• gene expression analysis

• reverse transcriptase-polymerase chain reaction

Other:
• fluorophotometry

• laboratory biomarker analysis

• mass spectrometry

Procedure:
• adjuvant therapy

• quality-of-life assessment

Locations

Country	Name	City	State
United States	Mayo Clinic Cancer Research Consortium	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Johnson BS, Dueck AC, Dakhil SR, et al.: Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: initial safety data from the Mayo Clinic Cancer Research Conso

McCullough A, Dueck A, Chen B, et al.: HER-2 central confirmatory testing using ASCO/CAP guidelines for trastuzumab/lapatinib trial MCCR RC0639. [Abstract] J Clin Oncol 27 (Suppl 15): A-e11527, 2009.

Palmieri FM, Dueck AC, Johnson DB, et al.: Cardiac safety of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the Mayo Clinic Cancer Research Consortium Trial R

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment		6 months
Secondary	Adverse Event Profile as Measured by NCI CTCAE v 3.0	Measured by number of patients with at least one with grade 3+, Grade 4+, Hem, and Non-Hem AEs.	5 years
Secondary	Cumulative Incidence (CI) of Cardiac Events	Evaluable patients included those completed the AC phase of their treatment regimen; with post AC cardiac evaluation indicates they are eligible to begin treatment with PTL; and those have begun their post-AC therapy.; Cardiac events: symptomatic congestive heart failure (CHF), cardiac death and other cardiac events (NCI Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3)	5 years
Secondary	Number of Patients Who Experience >= 10 Percent Drop in Left Ventricular Ejection Fraction (LVEF)	Number of Patients Who Experience >= 10 Percent Drop in Left Ventricular Ejection Fraction (LVEF) from baseline to any post-baseline time point.	5 years
Secondary	Percentage of Participants With Disease-Free Survival (DFS)	DFS was defined as the time from registration to the earliest date of documentation of any local, regional, or distant recurrence of breast cancer (BC); the development of a contralateral BC or second primary other than squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix, or lobular carcinoma in situ of the breast; or death from any cause without the documentation of one of these events. Participants were followed for a maximum of 5 years from randomization. The median OS with 95%CI was estimated using the Kaplan Meier method.	5 years
Secondary	Percentage of Participants With Overall Survival (OS)	OS was defined as the time from registration to death of any cause. Participants were followed for a maximum of 5 years from randomization. The median OS with 95%CI was estimated using the Kaplan Meier method.	5 years
Secondary	Change in Overall LINEAR ANALOGUE SELF ASSESSMENT (LASA) and Change in Symptom Distress Scale (SDS) Overall QOL	LASA score is from 0-90 with 0 being the worst and 90 being the best. SDS score is from 13-65 with 65 being the worst and 13 being the best.	5 years
Secondary	Proportion of Patients Experienced a Significant Decline in LINEAR ANALOGUE SELF ASSESSMENT (LASA) and a Overall Symptom Distress Scale (SDS) QOL Measurements	Overall Symptom Distress Scale (SDS) QOL Measurement and Overall LINEAR ANALOGUE SELF ASSESSMENT (LASA) QOL Measurement	5 years
Secondary	Incidence of Pulmonary Events	Pulmonary events to be included were grade 3 and higher pulmonary adverse events at least possibly related to study treatment, which occur at any time after post-AC treatment is begun, but prior to documentation of a breast cancer recurrence, contralateral breast cancer, secondary primary cancer, non-pulmonary death, or pulmonary death not related to study treatment.	5 years